Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odanacatib BMD and Micro-architecture Study
NCT00729183Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of odanacatib in osteoporosis, sponsored by Merck & Co.. Started Oct 2008; status: completed.
02
Drugs
odanacatib
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00729183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00729183.